Research Article - Biomedical Research (2017) Volume 28, Issue 20
Usage rates of treatments for cardiovascular prevention in patients with type 2 diabetes mellitus without diagnosis of coronary artery disease
Aim: The aim of this study is to retrospectively investigate the usage rates of antidiabetic treatments, and statin, aspirin and angiotensin (angiotensin converting enzyme inhibitors and angiotensin receptor blockers) based treatments for cardiovascular prevention in patients with type 2 diabetes mellitus.
Material and Methods: Drug exemption reports issued during 2015 and 2016 were evaluated from the hospital's digital database. Among these reports, files of patients with the DM diagnosis code (E11-E14) and without any diagnosis that could be associated with major cardiac events were scanned, and approximately 31685 records were obtained.
Results: A total of 11942 individuals were selected randomly according to simple random sampling method, and the active ingredients of the drugs listed in the drug exemption reports and used by the selected individuals were investigated. When usage in all groups was investigated, it was found that 21.3% of the patients used statin, 26.08% used ACE-I/ARB, and 9.8% used aspirin.
Discussion: In conclusion, the use of multiple treatments such as statins, angiotensinogen-dependent treatments, and aspirin in patients with DM2 is associated with a reduction in all-cause mortality. Secondary prevention, however, depends on the early selection of cases, and the initiation of appropriate preventive treatments; progression of the disease can only be stopped this way.Author(s): Dilek Oztas, Mehmet Kayhan, Huseyin Balcioglu, Yasemin Saglan, Yunus Emre Sari, Ugur Bilge